Skip to content
HowShorted

ALDER BIOPHARMACEUTICALS INC short interest in 2018

In 2018, ALDER BIOPHARMACEUTICALS INC's disclosed short interest ran from 9.18% of shares outstanding on 12 Jan 2018 to 16.92% on 31 Dec 2018, a change of +7.74 percentage points. The year's high was 17.87% on 15 Jun 2018 and its low 9.18% on 12 Jan 2018, averaging 15.38% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.94 days on 30 Nov 2018. Full history: ALDER BIOPHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019

Aggregate net short position time series for ALDER BIOPHARMACEUTICALS INC in 2018

2018 in figures

Start of year
9.18% (12 Jan 2018)
End of year
16.92% (31 Dec 2018)
Change
+7.74 pp
High
17.87% (15 Jun 2018)
Low
9.18% (12 Jan 2018)
Average
15.38%
Highest days to cover
24.94 (30 Nov 2018)
SEC filings marked
8

Every report in 2018

ALDER BIOPHARMACEUTICALS INC short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20189.18%2.51
31 Jan 20189.46%3.58
15 Feb 201811.50%3.81
28 Feb 201812.32%5.8510-K filed, results (8-K)
15 Mar 201813.62%8.00
29 Mar 201816.03%5.42
13 Apr 201816.25%10.29
30 Apr 201816.69%12.81
15 May 201816.67%12.8410-Q filed, results (8-K)
31 May 201816.82%10.60
15 Jun 201817.87%7.52
29 Jun 201816.02%11.42
13 Jul 201815.73%12.40
31 Jul 201815.92%17.16
15 Aug 201815.75%10.7410-Q filed, results (8-K)
31 Aug 201815.69%16.73
14 Sep 201815.78%13.72
28 Sep 201816.39%13.73
15 Oct 201815.99%11.40
31 Oct 201816.89%15.88
15 Nov 201817.81%15.3610-Q filed, results (8-K)
30 Nov 201817.77%24.94
14 Dec 201816.07%9.96
31 Dec 201816.92%10.68

See also: ALDER BIOPHARMACEUTICALS INC's full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.